REG - Polarean Imaging PLC - Notice of Results

Polarean ImagingAnnouncement

25/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250425:nRSY1055Ga&default-theme=true

RNS Number : 1055G  Polarean Imaging PLC  25 April 2025

25 April 2025

Polarean Imaging Plc

("Polarean" or the "Company")

 

Notice of results

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging
technology leader in advanced Magnetic Resonance Imaging ("MRI") of lung
function, confirms that it will be announcing its full year results for the
year ended 30 December 2024 on Thursday, 8 May 2025.

 

Christopher von Jako, PhD, Chief Executive Officer, and Charles Osborne, Chief
Financial Officer, will be hosting a live online presentation relating to the
results via the Investor Meet Company platform on Thursday, 8 May 2025 at
15.00 BST.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your IMC dashboard up until 9.00 BST the day
before the meeting or in real time during the presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet
Polarean Imaging Plc here
(https://www.investormeetcompany.com/polarean-imaging-plc/register-investor) .
Investors who already follow Polarean on the Investor Meet Company platform
will automatically be invited.

 

Whilst the Company may not be in a position to answer every question it
receives, it will address the most prominent within the confines of
information already disclosed to the market through regulatory notifications.
A recording of the presentation will be available on the Investor Meet Company
platform afterwards.

 

Enquiries:

 

  Polarean Imaging Plc                                       www.polarean.com / www.polarean-ir.com
 Christopher von Jako, PhD, Chief Executive Officer          Via Walbrook PR
 Charles Osborne, Chief Financial Officer

  Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)               +44 (0)20 7710 7600
 Nicholas Moore / Nick Harland / Brough Ransom / Ben Good

 Walbrook PR         Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
 Anna Dunphy / Paul McManus              Mob: +44 (0)7876 741 001 / +44 (0) 7980 541 893

 

About Polarean

Polarean is a revenue-generating medical imaging technology company
revolutionising pulmonary medicine through direct visualisation of lung
function by introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern solutions
to accurately assess lung function. The Company strives to optimise lung
health and prevent avoidable loss by illuminating hidden disease, addressing
the global unmet medical needs of more than 500 million patients worldwide
suffering from chronic respiratory disease. Polarean is a leader in the field
of hyperpolarisation science and has successfully developed the first and only
hyperpolarised Xenon MRI inhaled contrast agent, XENOVIEW®, which is now
FDA-approved in the United States. Polarean is dedicated to researching,
developing, and commercialising innovative imaging solutions with its
non-invasive and radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary Xenon gas
blend, gas hyperpolarisation system, as well as software and accessories,
facilitating fully integrated modern respiratory imaging operations. Founded
in 2012, with offices in Durham, NC, and London, United Kingdom, Polarean is
committed to increasing global awareness of and broad access to its XENOVIEW
MRI technology platform. For the latest news and information about Polarean,
please visit www.polarean.com (http://www.polarean.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKZGZDFDRGKZM